The round was also backed by existing investors Bay City Capital, Aberdare Ventures, and New Leaf Venture Partners.
The company said the round came after it hit revenue milestones ahead of schedule. It will use the proceeds to develop commercial infrastructure and launch its MIRISK VP cardiac risk assessment in international markets.
Aviir CEO Douglas Harrington said, “Our pilot and regional launch programs have generated both enthusiastic response among the physician community and commercial adoption.
“The additional funding will now allow us to conduct a more broad commercial launch domestically and take the next steps toward a comprehensive international distribution plan to be rolled out later this year.”
Earlier this week Merck led a $15m Series B for cloud-based health monitoring platform Medivo.
Copyright © 2013 AltAssets